Genentech broke ground in February of 2023 on a $280 million biologics manufacturing center in Oceanside, Calif. The small-batch facility will utilize single-use bioreactors for the commercial production of innovative therapeutics such as personalized medicines and treatments for rare diseases. Featuring advanced automation platforms and digital technologies, the 84,000-sf plant will leverage in-house process improvements to achieve increased flexibility, speed, and output. Strategically located near the company's Clinical Supply Center in South San Francisco, the building's standardized design will enable production to be transferred between the two sites in a matter of days instead of the traditional 18-month timeline.
The highly sustainable development is expected to use 25 percent less energy and 28 percent less water than a conventional structure, with zero plastic waste going to landfill. Part of a $450 million investment to increase capacity on the Oceanside campus, the bioprocessing center will accommodate 150 new full-time employees when operations commence in early 2025.
Genentech is a subsidiary of Hoffman-La Roche, a global pharmaceutical firm based in Switzerland.
